• Cazzola, M. (2007) Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis. Hematologica, 92, 15851589.
  • Chen, M., Cheng, A., Candotti, F., Zhou, Y.J., Hymel, A., Fasth, A., Notarangelo, L.D. & O’Shea, J.J. (2000) Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Molecular and Cellular Biology, 20, 947956.
  • Huse, M. & Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell, 109, 275282.
  • Ihle, J.N. (1995) Cytokine receptor signalling. Nature, 377, 591594.
  • Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D’Andrea, A., Fröhling, S., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliand, G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387397.
  • Lindauer, K., Loerting, T., Liedl, K.R. & Kroemer, R.T. (2001) Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Engineering, 14, 2737.
  • Luo, H., Rose, P., Barber, D., Hanratty, W.P., Lee, S., Roberts, T.M., D’Andrea, A. & Dearolf, C.R. (1997) Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Molecular and Cellular Biology, 17, 15621571.
  • Reiter, A., Walz, C., Watmore, A., Schoch, C., Blau, I., Schlegelberger, B., Berger, U., Telford, N., Aruliah, S., Yin, J.A., Vanstraelen, D., Barker, H.F., Taylor, P.C., O’Driscoll, A., Benedetti, F., Rudolph, C., Kolb, H.J., Hochhaus, A., Hehlmann, R., Chase, A. & Cross, N.C. (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Research, 65, 26622667.
  • Saharinen, P. & Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. The Journal of Biological Chemistry, 277, 4795447963.
  • Saharinen, P., Takaluoma, K. & Silvennoinen, O. (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Molecular and Cellular Biology, 20, 33873395.
  • Saharinen, P., Vihinen, M. & Silvennoinen, O. (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Molecular Biology of the Cell, 14, 14481459.
  • Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England Journal of Medicine, 356, 459468.